Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.

Véronique JolyValentine M FerreQuentin Le HingratGilles PeytavinMélanie CrestaCharlotte CharpentierMarc DigumberFlorence DamondYazdan YazdanpanahSophie MatheronDiane DescampsJade Ghosn

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

This retrospective study evaluated Bictegravir/FTC/TAF in 24 PWHIV, 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load < 40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of Bictegravir/FTC/TAF to treat HIV-2 infection.

Keyphrases

antiretroviral therapy
hiv infected
induced apoptosis
cell cycle arrest
randomized controlled trial
hiv infected patients
systematic review
peripheral blood
cell death
signaling pathway
cell proliferation
nk cells
pi k akt